News
Egyptian Drug Authority Chairman Discusses Enhancing Cooperation in Vaccine Development, Manufacturing, and Technology Localization with CEPI and Minapharm
Dr. Ali El-Ghamrawy, Chairman Of the Egyptian Drug Authority, held a meeting with a delegation from the Coalition for Epidemic Preparedness Innovations (CEPI), headed by Dr. Amadou Sall, Executive Director, Process Development and Manufacturing at the coalition, with the participation of Dr. Wafik El-Bardisi, Chairman and Managing Director of Minapharm Pharmaceuticals. The meeting aimed to discuss prospects for joint cooperation in vaccine development and manufacturing, enhance local capabilities, discuss the EDA’s role in supporting the existing partnership between CEPI and Minapharm, and explore new opportunities for cooperation with Egypt.
Dr. Ali El-Ghamrawy emphasized the Egyptian Drug Authority’s commitment to support strategic partnerships in the field of vaccines and biological products, and to enhance cooperation with international institutions and specialized companies. This contributes to developing national capabilities in vaccine manufacturing, technology transfer, and localizing advanced biological industries, while ensuring compliance with applicable regulatory requirements and frameworks, thereby enhancing development and manufacturing sustainability and strengthening Egypt's position in this field.
For their part, representatives of CEPI and Minapharm praised the pivotal role played by the Egyptian Drug Authority in supporting the development of pharmaceutical and biological industries, as well as its advanced regulatory expertise and technical competencies that contribute to creating a supportive environment for vaccine development and manufacturing. They emphasized the importance of cooperating with the EAD to enhance strategic partnerships, exchange expertise, support technology transfer, and develop local manufacturing capabilities, thereby contributing to achieving shared objectives in epidemic preparedness and enhancing health security.
The meeting reviewed existing cooperation between CEPI and Minapharm, and exchanged views and expertise regarding the regulatory frameworks and requirements governing vaccine development and manufacturing, including products developed or manufactured under licensing agreements. It also discussed the regulatory and technical procedures associated with moving the project into its executive phases, ensuring compliance with approved technical and regulatory standards.
The CEPI delegation included Dr. Raafat Fahim, Senior Advisor, Process Development and Manufacturing, and Mr. Neren Rau, Policy Director.
This comes within the framework of the Egyptian Drug Authority’s strategy to enhance international cooperation, build strategic partnerships in the field of vaccines and biological products, support the localization of advanced pharmaceutical and biological industries, and promote technology transfer. This contributes to developing national manufacturing capabilities, enhancing the competitiveness of the Egyptian pharmaceutical industry, strengthening Egypt's position as a regional hub for vaccine development and manufacturing, and supporting efforts to achieve sustainable health security.
Tags
The Egyptian Drug Authority (EDA)
Coalition for Epidemic Preparedness Innovations (CEPI)
Minapharm